TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

TG Therapeutics, Inc.NASDAQ: TGTX

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income declines year over year

Q3 FY2026 net income of $55.46M fell 85.8% year over year, behind the -76.3% change in trailing-twelve-month net income. Sequentially, it rose 612.8% from the prior quarter.

Context

  • Net income amounted to 72.6% of revenue in FY2025, up 65.5 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of $151.85M (-66.0%) for the fiscal year ending Dec 2026, a slowdown from the +1812.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$55.46M+612.8% QoQ
Last fiscal yearDec 2025
$447.18M+1812.4% YoY
LTMSep 2026
$106.06M-76.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-85.8%+227.6%+313.4 pp
1 year+1812.4%-66.0%-1878.5 pp
3-year CAGR—+6.0%—
5-year CAGR+12.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
447.18M USD
Year-over-year change
+1812.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -76.3% is the lowest of 7, against a peer median of +3.0%.
  • Net income amounts to 11.8% of revenue for TGTX, versus a peer median of 173.0%.
TGTX Competitors
Net Income for TGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$861.1M USD—-48.4%20.8%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$309.06M USD+37.6%+32.1%275948.2%
ADCTADC Therapeutics S.A.LTM Mar 2026$136.99M USD-8.6%-3.2%173.0%
TGTXTG Therapeutics, Inc.LTM Sep 2026$106.06M USD-76.3%—11.8%
XNCRXencor, Inc.LTM Jun 2026$71.19M USD-60.8%+18.5%67.8%
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
IPHAInnate Pharma S.A.FY2025€49.18M EUR-0.6%-5.4%1764.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$44.17M USD+6.7%-28.2%—
ADAGAdagene Inc.LTM Jun 2024$31.85M USD—-39.6%3904.3%
Peer median (excluding TGTX) —+3.0%-10.0%173.0%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(348.1M)(198.34M)12.67M23.38M447.18M
Depreciation & Amortization494K515K423K280K244K
Deferred Income Tax517K000(348M)
Stock-Based Compensation61.27M19.19M37.93M42.54M64.67M
Change in Working Capital(12.22M)(1.65M)(84.66M)(109.3M)(194.54M)
Accounts Receivables(1.39M)1.39M(51.09M)(78.09M)(176.44M)
Inventory(15.99M)0(36.94M)(66.85M)(33.45M)
Accounts Payables15.99M(11.01M)192K055.88M
Other Working Capital(10.83M)7.97M3.18M35.65M(40.52M)
Other Non-Cash Items2.4M4.11M2.22M2.58M5.67M
Operating Cash Flow(295.63M)(176.17M)(31.41M)(40.52M)(24.77M)
Capital Expenditures(401K)(14K)0(45K)(214K)
Acquisitions (Net)(69K)20M000
Purchases of Investments(55.53M)(107.27M)(146.88M)(311.89M)(223.49M)
Sales of Investments55.6M87.28M96.23M310.9M237.5M
Other Investing Activities69K(20M)000
Investing Cash Flow(332K)(20.01M)(50.65M)(1.04M)13.8M
Debt Repayment40M(975K)25M137.26M0
Common Stock Issued2.22M584K46.3M01.51M
Common Stock Repurchased000(8.76M)(91.24M)
Dividends Paid00000
Other Financing Activities(800K)01.41M25K0
Financing Cash Flow41.42M(391K)72.71M128.53M(89.73M)
Effect of Forex Changes00000
Net Change in Cash(254.55M)(196.57M)(9.36M)86.97M(100.7M)
Free Cash Flow(296.04M)(176.18M)(31.41M)(40.56M)(24.99M)

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.